Suppr超能文献

印度维沙卡帕特南一家三级护理医院在解锁 2.0 后收治的 COVID-19 患者的临床和生化特征-一项回顾性研究。

Clinical and biochemical profile of COVID-19 patients admitted in a tertiary care hospital in Visakhapatnam, India during post unlock 2.0 - a retrospective study.

机构信息

Department of General Medicine, Gitam Institute of Medical Sciences and Research, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam, India.

Department of Respiratory Medicine, Gitam Institute of Medical Sciences and Research, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam, India.

出版信息

J Med Life. 2022 Feb;15(2):264-268. doi: 10.25122/jml-2021-0341.

Abstract

There have been more than 31378143 confirmed coronavirus disease 2019 (COVID-19) cases in India. It was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Because the risk of severe COVID-19 is not consistent across all individuals, uncertainty is linked to disease development. COVID-19 results have been related to systemic inflammation as a predictor. In COVID-19, increased levels of inflammatory markers have been associated with cytokine storm, coagulopathy, and endothelial dysfunction. A significant amount of research suggests that these results have a role in the cause of death in individuals suffering from a severe form of COVID-19. We aim to show our experience of COVID-19 at GITAM Institute of Medical Sciences and Research (GIMSR), Visakhapatnam. We analyzed data on 558 patients admitted to our dedicated COVID hospital during post unlock (UL) 2.0 in India from August 2 to August 31, 2020. The mean age was 43.65 years; 69% of them were male. Using MoHFW India severity guidelines, 68.10% were mild, 18.64% were moderate, and 13.26% were severe cases. Fatigue (66.13%) was the most common complaint, followed by anosmia (63.80%), fever (57.53%), diarrhea (56.09%), shortness of breath (22.40%), and others. The most common preexisting comorbidity seen in our patients was diabetes mellitus and hypertension, respectively. Laboratory parameters revealed mean hemoglobin of 13.04±1.91 gm/dl, mean total leukocyte count of 7378.49±3229 cells/cumm, mean platelet count of 2.3±0.8 lakhs/cumm, mean erythrocyte sediment rate of 40±30 mm/hr, mean ferritin level of 335.96 ng/ml, mean D-dimer level of 794.88 ng/ml and mean CRP of 23.27 mg/l. Severity was associated with higher age, symptomatic presentation, elevated leucocytes, and elevated inflammatory markers.

摘要

印度已报告超过 31378143 例 2019 年冠状病毒病(COVID-19)确诊病例。世界卫生组织(WHO)于 2020 年 3 月 11 日宣布 COVID-19 疫情为大流行。由于 COVID-19 重症风险并非在所有个体中都一致,因此疾病的发展存在不确定性。COVID-19 结果与作为预测因子的全身炎症相关。在 COVID-19 中,炎症标志物水平升高与细胞因子风暴、凝血障碍和血管内皮功能障碍相关。大量研究表明,这些结果在 COVID-19 重症患者的死亡原因中起作用。我们旨在展示在印度解锁后 2.0 期间,位于维沙卡帕特南的 GITAM 医学科学与研究所(GIMSR)的 COVID-19 经验。我们分析了 2020 年 8 月 2 日至 8 月 31 日期间,在我们的专门 COVID 医院收治的 558 名住院患者的数据。平均年龄为 43.65 岁;其中 69%为男性。根据 MoHFW 印度严重程度指南,68.10%为轻症,18.64%为中度,13.26%为重症。疲劳(66.13%)是最常见的主诉,其次是嗅觉丧失(63.80%)、发热(57.53%)、腹泻(56.09%)、呼吸急促(22.40%)和其他症状。我们的患者中最常见的既往合并症分别是糖尿病和高血压。实验室参数显示平均血红蛋白为 13.04±1.91g/dl,平均总白细胞计数为 7378.49±3229 个/立方毫米,平均血小板计数为 2.3±0.8 十万个/立方毫米,平均红细胞沉降率为 40±30mm/hr,平均铁蛋白水平为 335.96ng/ml,平均 D-二聚体水平为 794.88ng/ml,平均 CRP 为 23.27mg/l。严重程度与较高的年龄、有症状表现、白细胞升高和炎症标志物升高相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55c5/8999106/4e92a08f146c/JMedLife-15-264-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验